RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA
Clinical trials for RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat uterine cancer
Disease control OngoingThis study is testing whether combining two drugs, niraparib and dostarlimab, can help control a specific, aggressive type of uterine cancer that has returned or persisted after standard chemotherapy. The goal is to see if this combination can shrink tumors and delay cancer growt…
Matched conditions: RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Casey Cosgrove • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Cancer-Killing virus tested in women with advanced uterine cancer
Disease control OngoingThis early-stage trial is testing the safety and best dose of a specially engineered virus designed to infect and kill endometrial cancer cells while sparing healthy ones. The virus can be tracked in the body using imaging. Some participants also receive an oral drug that may hel…
Matched conditions: RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Major trial tests new weapon against advanced uterine cancer
Disease control OngoingThis large, late-stage study is testing whether adding an immunotherapy drug called pembrolizumab to standard chemotherapy works better for treating advanced or recurrent endometrial cancer. It involves over 800 patients with stage III, IV, or returning cancer. The goal is to see…
Matched conditions: RECURRENT ENDOMETRIAL SEROUS ADENOCARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC